Last reviewed · How we verify
TCH chemotherapy
TCH is a chemotherapy regimen combining docetaxel, carboplatin, and trastuzumab to kill cancer cells and target HER2-positive tumors.
TCH is a chemotherapy regimen combining docetaxel, carboplatin, and trastuzumab to kill cancer cells and target HER2-positive tumors. Used for HER2-positive breast cancer (early-stage and metastatic).
At a glance
| Generic name | TCH chemotherapy |
|---|---|
| Sponsor | Agendia |
| Drug class | Chemotherapy regimen (combination) |
| Target | HER2, microtubule, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
TCH combines three agents: docetaxel (a taxane microtubule inhibitor), carboplatin (a platinum-based DNA-damaging agent), and trastuzumab (a HER2-targeted monoclonal antibody). This combination provides both cytotoxic chemotherapy and targeted therapy against HER2-overexpressing breast cancer cells, enhancing treatment efficacy in HER2-positive disease.
Approved indications
- HER2-positive breast cancer (early-stage and metastatic)
Common side effects
- Neutropenia
- Anemia
- Neuropathy
- Nausea/vomiting
- Cardiotoxicity (trastuzumab-related)
- Fatigue
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma
- Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer (PHASE2)
- BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (PHASE3)
- A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (PHASE3)
- MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (PHASE4)
- A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer (PHASE2)
- Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TCH chemotherapy CI brief — competitive landscape report
- TCH chemotherapy updates RSS · CI watch RSS
- Agendia portfolio CI